Some HCV Treatment Gaps Emerging With New All-Oral Antiviral Regimens
Executive Summary
Competing direct-acting antiviral therapy combinations are solving many of the treatment issues in HCV, but numerous questions remain, an NEJM editorial notes. Cirrhotic patients have relatively low response rates, while genotype 3 remains much harder to cure than other genotypes, especially among null-responders.